Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine |
| |
Authors: | Dr Med C Jaspers R Haase H Pfingsten G Benker D Reinwein |
| |
Affiliation: | (1) Abteilung für Klinische Endokrinologie, Medizinischen Universitätsklinik, Hufelandstrasse 55, W-4300 Essen, Germany |
| |
Abstract: | Summary We studied the efficacy and tolerability of a repeatable long-acting parenteral depot-bromocriptine preparation (Parlodel LAR) in 14 acromegalic patients, 10 of whom had received oral bromocriptine therapy previously, 2 of them showing intolerance to oral bromocriptine. Patients received i.m. injections of 50–100 mg depot-bromocriptine at 4-week intervals for 3–24 months (median 6). Growth hormone profiles were assessed by four daily samples at 4-week intervals. Main daily growth hormone levels decreased from 52.1 ±12.3 g/l (mean ± SEM) to 19.4 ± 4.7 g/l on the day of injection. In 6 patients, growth hormone values were lowered by more than 50%, whereas IGF-I levels decreased only slightly and growth hormone values during the oral glucose tolerance test remained non-suppressible. Tumour sizes were not affected. Two women became pregnant and were delivered of healthy babies. Side-effects typical of bromocriptine occurred frequently on the days of injection and diminished in most patients after 2 months of therapy despite increasing dosage. Compared with previous oral bromocriptine therapy, 9 of 10 patients preferred the depot preparation, whereas the reduction of growth hormone levels was similar during both treatments. In conclusion, depot-bromocriptine should be considered for acromegalic patients intolerant to oral bromocriptine.Abbreviations br
Bromocriptine
- oral br.
oral bromocriptine
- depot-br.
depot-bromocriptine
- GH
growth hormone
- oGTT
oral glucose tolerance test
- GnRH
gonadotropin-releasing hormone
- TRH
thyrotropin-releasing hormone |
| |
Keywords: | Depot-bromocriptine Acromegaly Pregnancy |
本文献已被 SpringerLink 等数据库收录! |
|